Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.

Details

Serval ID
serval:BIB_D6D634194460
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
Journal
International journal of molecular sciences
Author(s)
Cristina V., Herrera-Gómez R.G., Szturz P., Espeli V., Siano M.
ISSN
1422-0067 (Electronic)
ISSN-L
1422-0067
Publication state
Published
Issued date
30/10/2019
Peer-reviewed
Oui
Volume
20
Number
21
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory recurrent/metastatic (R/M) HNSCC. Furthermore, checkpoint inhibitors are better tolerated than chemotherapy. The state of the art in the treatment of R/M HNSCC is changing, thanks to improved results for checkpoint inhibitors. Results for these treatments are also awaited in curative settings and for locally advanced HNSCC. Unfortunately, the response rate of immunotherapy is low. Therefore, the identification of predictive biomarkers of response and resistance to anti-PD1/PD-L1 is a key point for better selecting patients that would benefit the most from immunotherapy. Furthermore, the combination of checkpoint inhibitors with various agents is being currently evaluated to improve the response rate, prolong response duration, and even increase the chances for a cure. In this review, we summarize the most important results regarding immune targeting agents for HNSCC, predictive biomarkers for resistance to immune therapies, and future perspectives.
Keywords
Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/antagonists & inhibitors, Drug Resistance, Neoplasm, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/immunology, Humans, Immunotherapy, Neoplasm Recurrence, Local, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Squamous Cell Carcinoma of Head and Neck/drug therapy, Squamous Cell Carcinoma of Head and Neck/immunology, Treatment Outcome, combination treatment, head and neck cancer, immunotherapy
Pubmed
Web of science
Open Access
Yes
Create date
02/11/2019 22:55
Last modification date
06/12/2020 6:26
Usage data